Show results for
Refine by
Vaccine Producing Articles & Analysis
45 news found
The development of vaccines against superbugs is an important area of research because vaccines can help prevent infections from occurring in the first place and reduce the need for antibiotics. ...
BOC Sciences, a globally renowned supplier with over a decade of experience in the biochemical supply chain, is thrilled to announce its participation in this year's TIDES USA or the Oligonucleotide and Peptide Therapeutics conference. The BOC Sciences team will showcase its cutting-edge products and services at booth #937. TIDES USA 2024 is to be held in Boston from May 14 to 17, 2024, ...
Among the various vaccine technologies, mRNA vaccines have emerged as a groundbreaking solution, offering promising results in the fight against infectious diseases. ...
The global mRNA vaccine and therapeutics market was valued at USD 34.7 billion in 2022 and is expected to reach USD 68.1 billion by 2030, making this an extremely valuable potential opportunity for both companies to enter the rapidly expanding market for mRNA-based vaccines and therapies, said Mark Emalfarb, Dyadic’s Chief Executive Officer. ...
Alfa Chemistry, known as a chemical supplier for various high-quality chemicals and materials for both academia and the industry, has recently extended its offering scope to vaccine related products, including but not limited to: vaccine excipients, nucleic acid delivery excipients, cell culture media and pharmaceutical packaging. “Always bearing in mind that what customers truly need is the top ...
Ampoules from the master Cell Bank are used to produce larger working Cell Banks that can be used for manufacturing purposes. ...
ByNuvonis
It takes between 8 to 36 months to produce, package and deliver vaccines to those who need them. This timeline includes testing each batch of vaccine at every step of its manufacturing process, and repeated quality control of batches by different authorities in the respective countries. ...
ByNuvonis
Therefore, when the more transmissible Omicron BA.1 sublineage hit back in February, population immunity from infection was low. This, combined with a low vaccine coverage, led to a huge wave of both infections and deaths, especially amongst the elderly. Mainland China has very low levels of immunity across its population. Its citizens were vaccinated with ...
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery ...
Join us when we are expanding our unit with another Clinical Project Manager. In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and ...
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the ...
Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics (“LightDeck”), a pioneer in innovative planar waveguide ...
IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, and University of Antwerp today announce that they have entered into a collaboration agreement to research and develop a dynamic lipid library for optimized delivery systems ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced that preclinical data from ZIP1642, its COVID-19 vaccine candidate, was published in the renowned scientific journal Molecular Therapy. The paper entitled ...
The VSE™ formulation is tailor-made to optimize the scalability of the NRC’s AAV manufacturing process and produce the next-generation gene therapy for LPLD. “The NRC offers Canadian businesses access to unique expertise in this area, as well as outstanding research and manufacturing facilities. It will be exciting to see the NRC use our VSEs to ...
(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Cancer Research UK recently completed patient enrollment in the ongoing Phase 1 clinical trial of VAC2, an allogeneic cancer vaccine product candidate, for the treatment of non-small cell lung cancer (“NSCLC”). ...
IRVINE, Calif. – Apr. 5, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors. Dr. Fibiger served as vice president and global head of neuroscience at Amgen, the world’s largest ...
IRVINE, Calif. – Mar. 9, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego. Dr. Keirstead is scheduled to deliver an opening ...